Coloplast A Stock Revenue
| CLPBY Stock | USD 8.53 0.01 0.12% |
As of the 27th of January, Coloplast shows the Risk Adjusted Performance of (0.03), standard deviation of 1.41, and Mean Deviation of 1.0. Coloplast A technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Coloplast's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Coloplast's valuation are provided below:Coloplast A does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Coloplast |
Coloplast 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Coloplast's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Coloplast.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Coloplast on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Coloplast A or generate 0.0% return on investment in Coloplast over 90 days. Coloplast is related to or competes with Straumann Holding, Straumann Holding, Terumo, Terumo Corp, Sartorius Aktiengesellscha, Sartorius Stedim, and Orion Oyj. Coloplast AS engages in the development and sale of intimate healthcare products and services in Denmark, the United Sta... More
Coloplast Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Coloplast's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Coloplast A upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 9.86 | |||
| Value At Risk | (2.31) | |||
| Potential Upside | 1.73 |
Coloplast Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Coloplast's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Coloplast's standard deviation. In reality, there are many statistical measures that can use Coloplast historical prices to predict the future Coloplast's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.21) | |||
| Treynor Ratio | (0.11) |
Coloplast January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 1.0 | |||
| Coefficient Of Variation | (2,123) | |||
| Standard Deviation | 1.41 | |||
| Variance | 1.98 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.21) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 9.86 | |||
| Value At Risk | (2.31) | |||
| Potential Upside | 1.73 | |||
| Skewness | (0.33) | |||
| Kurtosis | 3.47 |
Coloplast A Backtested Returns
Coloplast A secures Sharpe Ratio (or Efficiency) of -0.0517, which signifies that the company had a -0.0517 % return per unit of risk over the last 3 months. Coloplast A exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Coloplast's Risk Adjusted Performance of (0.03), standard deviation of 1.41, and Mean Deviation of 1.0 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.72, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Coloplast's returns are expected to increase less than the market. However, during the bear market, the loss of holding Coloplast is expected to be smaller as well. At this point, Coloplast A has a negative expected return of -0.0752%. Please make sure to confirm Coloplast's value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Coloplast A performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.32 |
Poor reverse predictability
Coloplast A has poor reverse predictability. Overlapping area represents the amount of predictability between Coloplast time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Coloplast A price movement. The serial correlation of -0.32 indicates that nearly 32.0% of current Coloplast price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.32 | |
| Spearman Rank Test | 0.08 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Coloplast A reported 22.58 B of revenue. This is 196.05% higher than that of the Healthcare sector and significantly higher than that of the Medical Instruments & Supplies industry. The revenue for all United States stocks is 139.31% lower than that of the firm.
Coloplast Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Coloplast's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Coloplast could also be used in its relative valuation, which is a method of valuing Coloplast by comparing valuation metrics of similar companies.Coloplast is currently under evaluation in revenue category among its peers.
Coloplast Fundamentals
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 28.84 B | |||
| Shares Outstanding | 2.12 B | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 37.95 X | |||
| Price To Book | 22.46 X | |||
| Price To Sales | 1.13 X | |||
| Revenue | 22.58 B | |||
| Gross Profit | 15.53 B | |||
| EBITDA | 7.23 B | |||
| Net Income | 4.71 B | |||
| Cash And Equivalents | 854 M | |||
| Cash Per Share | 0.40 X | |||
| Total Debt | 16.36 B | |||
| Debt To Equity | 2.83 % | |||
| Current Ratio | 1.01 X | |||
| Book Value Per Share | 2.78 X | |||
| Cash Flow From Operations | 5.1 B | |||
| Earnings Per Share | 0.31 X | |||
| Price To Earnings To Growth | 3.39 X | |||
| Number Of Employees | 14.5 K | |||
| Beta | 0.21 | |||
| Market Capitalization | 24.94 B | |||
| Total Asset | 34.96 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 2.11 % | |||
| Net Asset | 34.96 B | |||
| Last Dividend Paid | 20.0 |
About Coloplast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coloplast A's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coloplast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coloplast A based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Additional Tools for Coloplast Pink Sheet Analysis
When running Coloplast's price analysis, check to measure Coloplast's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coloplast is operating at the current time. Most of Coloplast's value examination focuses on studying past and present price action to predict the probability of Coloplast's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coloplast's price. Additionally, you may evaluate how the addition of Coloplast to your portfolios can decrease your overall portfolio volatility.